DK0782709T3 - Detektering af cancer - Google Patents

Detektering af cancer

Info

Publication number
DK0782709T3
DK0782709T3 DK95940906.1T DK95940906T DK0782709T3 DK 0782709 T3 DK0782709 T3 DK 0782709T3 DK 95940906 T DK95940906 T DK 95940906T DK 0782709 T3 DK0782709 T3 DK 0782709T3
Authority
DK
Denmark
Prior art keywords
patient
afp
cancer cells
introducing
labeled
Prior art date
Application number
DK95940906.1T
Other languages
English (en)
Inventor
Ricardo J Moro
Original Assignee
Ricardo J Moro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ricardo J Moro filed Critical Ricardo J Moro
Application granted granted Critical
Publication of DK0782709T3 publication Critical patent/DK0782709T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5757—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncofoetal proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/92—Detection of biochemical

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Optics & Photonics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK95940906.1T 1994-09-19 1995-09-18 Detektering af cancer DK0782709T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30814194A 1994-09-19 1994-09-19
PCT/IB1995/000902 WO1996009551A1 (en) 1994-09-19 1995-09-18 Detection and treatment of cancer

Publications (1)

Publication Number Publication Date
DK0782709T3 true DK0782709T3 (da) 2010-03-29

Family

ID=23192727

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95940906.1T DK0782709T3 (da) 1994-09-19 1995-09-18 Detektering af cancer

Country Status (15)

Country Link
US (1) US6514685B1 (da)
EP (3) EP1955714A1 (da)
KR (1) KR970706498A (da)
CN (2) CN100472213C (da)
AT (1) ATE449342T1 (da)
AU (1) AU714966B2 (da)
BR (1) BR9508959A (da)
CA (1) CA2197490A1 (da)
DE (1) DE69536019D1 (da)
DK (1) DK0782709T3 (da)
ES (1) ES2336976T3 (da)
FI (1) FI121353B (da)
NO (1) NO323754B1 (da)
RU (1) RU2161042C2 (da)
WO (1) WO1996009551A1 (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115399B2 (en) * 2001-07-31 2006-10-03 Allergan, Inc. Pinna reflex assay
WO2003060477A2 (en) * 2002-01-10 2003-07-24 The Regents Of The University Of California Iterative optical based histology
WO2004067716A2 (en) * 2003-01-24 2004-08-12 Agensys, Inc. Nucleic acids and corresponding proteins entitled 254p1d6b useful in treatment and detection of cancer
CN100360684C (zh) * 2005-02-01 2008-01-09 合肥中科大生物技术有限公司 甲胎蛋白(AFP)mRNA荧光定量RT-PCR检测试剂盒
PL2118123T3 (pl) 2007-01-31 2016-06-30 Dana Farber Cancer Inst Inc Stabilizowane peptydy p53 i ich zastosowania
JP5631201B2 (ja) 2007-03-28 2014-11-26 プレジデント アンド フェローズ オブ ハーバード カレッジ ステッチングされたポリペプチド
RU2377962C1 (ru) * 2008-06-10 2010-01-10 Государственное научное учреждение Всероссийский научно-исследовательский институт экспериментальной ветеринарии им. Я.Р. Коваленко РАСХН(ВИЭВ) Способ диагностики лейкоза крупного рогатого скота
PT2322221E (pt) 2008-08-05 2014-09-19 Toray Industries Composição farmacêutica para tratamento e prevenção de cancro
US11137401B2 (en) 2008-08-05 2021-10-05 Toray Industries, Inc. Method for detecting cancer using CAPRIN-1 as a marker
US11298113B2 (en) 2008-10-01 2022-04-12 Covidien Lp Device for needle biopsy with integrated needle protection
US9332973B2 (en) 2008-10-01 2016-05-10 Covidien Lp Needle biopsy device with exchangeable needle and integrated needle protection
US9186128B2 (en) 2008-10-01 2015-11-17 Covidien Lp Needle biopsy device
US9782565B2 (en) 2008-10-01 2017-10-10 Covidien Lp Endoscopic ultrasound-guided biliary access system
US8968210B2 (en) * 2008-10-01 2015-03-03 Covidien LLP Device for needle biopsy with integrated needle protection
JP2013505300A (ja) 2009-09-22 2013-02-14 エルロン・セラピューティクス・インコーポレイテッド ペプチド模倣大環状分子
AU2010309438A1 (en) * 2009-10-22 2012-06-07 Ricardo J. Moro Peptides that bind the alpha-fetoprotein (AFP) receptor and uses thereof
MX2012008991A (es) * 2010-02-04 2012-09-07 Toray Industries Medicamento para tratar y/o prevenir el cancer.
WO2012021144A1 (en) 2010-08-12 2012-02-16 New York University Oligooxopiperazines and methods of making and using them
KR102104762B1 (ko) 2010-08-13 2020-04-24 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
EP2741085B1 (en) 2011-08-04 2017-04-05 Toray Industries, Inc. Method for detecting pancreatic cancer
EP2768518A4 (en) 2011-10-18 2015-05-27 Aileron Therapeutics Inc PEPTIDOMIMETIC MACROCYCLES
CA2864120A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
RU2642299C2 (ru) 2012-02-15 2018-01-24 Эйлерон Терапьютикс, Инк. P53 пептидомиметические макроциклы
CN104334541A (zh) 2012-02-16 2015-02-04 纽约大学 使用低聚氧代哌嗪非肽螺旋模拟物对低氧诱导基因表达的控制
JP6244911B2 (ja) 2012-07-19 2017-12-13 東レ株式会社 癌の検出方法
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
HUE042081T2 (hu) 2013-08-09 2019-06-28 Toray Industries Gyógyászati készítmény rák kezelésére és/vagy megelõzésére
CN107106642B (zh) 2014-09-24 2021-02-26 艾瑞朗医疗公司 拟肽大环化合物及其制剂
EP3197478A4 (en) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
JP2018516844A (ja) 2015-03-20 2018-06-28 エルロン・セラピューティクス・インコーポレイテッドAileron Therapeutics,Inc. ペプチド模倣大環状分子およびその使用
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP3347372A4 (en) 2015-09-10 2019-09-04 Aileron Therapeutics, Inc. PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1
EP3371211B1 (en) 2015-11-04 2025-01-01 Icahn School of Medicine at Mount Sinai Rho-associated protein kinase ("rock") inhibitor for treating tumors and cancer, and identifying candidate subjects for such treatment
WO2017189730A1 (en) 2016-04-26 2017-11-02 Icahn School Of Medicine At Mount Sinai Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment
CN106290876B (zh) * 2016-08-11 2018-06-29 湖南新大陆生物技术有限公司 一种肿瘤细胞检测方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2682697B2 (ja) 1989-03-29 1997-11-26 積水化学工業株式会社 免疫測定試薬および免疫測定法
FR2701710B1 (fr) * 1993-02-18 1995-04-21 Intromed Ltd Conjugués protéiques, compositions les contenant et leurs applications en tant que médicament et réactif de diagnostic.

Also Published As

Publication number Publication date
ES2336976T3 (es) 2010-04-19
WO1996009551A1 (en) 1996-03-28
CA2197490A1 (en) 1996-03-28
RU2161042C2 (ru) 2000-12-27
ATE449342T1 (de) 2009-12-15
NO323754B1 (no) 2007-07-02
KR970706498A (ko) 1997-11-03
FI121353B (fi) 2010-10-15
BR9508959A (pt) 1997-12-30
EP1956374A1 (en) 2008-08-13
CN1132012C (zh) 2003-12-24
NO971256L (no) 1997-03-18
AU714966B2 (en) 2000-01-13
CN1169778A (zh) 1998-01-07
CN1502994A (zh) 2004-06-09
EP1955714A1 (en) 2008-08-13
US6514685B1 (en) 2003-02-04
AU3764895A (en) 1996-04-09
EP0782709A1 (en) 1997-07-09
NO971256D0 (no) 1997-03-18
CN100472213C (zh) 2009-03-25
EP0782709B1 (en) 2009-11-18
FI970990A0 (fi) 1997-03-10
DE69536019D1 (de) 2009-12-31
FI970990A7 (fi) 1997-03-10

Similar Documents

Publication Publication Date Title
ATE449342T1 (de) Nachweis von krebs
DK0943097T3 (da) Fremgangsmåde til at påvise IgE
ATE246356T1 (de) Vorrichtung zum vorhersagen von physiologischen messwerten
NO904001D0 (no) Fremgangsmaate og anordning for amperometrisk diagnoseanalyse.
ATE297950T1 (de) Testverfahren und reagenzien zur quantifizierung von hbnp
DE68923800D1 (de) Vorrichtung und verfahren zur bestimmung eines analyten in einer flüssigen probe mittels folgereaktionen.
NO940901L (no) Gensöker-biosensor-metode
ATE200151T1 (de) Analytische testvorrichtung einschliesslich negativ- und positivkontrolle
ATE129868T1 (de) Vorrichtung und verfahren zum nachweis von chemischen spezies.
RU97106059A (ru) Обнаружение и лечение рака
DK2154248T3 (da) Forbindelser og fremgangsmåder til diagnose af tuberkulose
DE3584796D1 (de) Verfahren und vorrichtung zur durchfuehrung analytischer bestimmungen.
DE69928250D1 (de) Analytisches verfahren unter verwendung von multipelviren-markierung
ATE157172T1 (de) Verwendung von monoclonalen rezeptoren gegen oncoproteinen zur überwachung von krebstherapie
HUP9800225A2 (hu) Eljárás és vegyületek analitok meghatározására remanenciaméréssel és ezek alkalmazásai
DE3485265D1 (de) Verfahren zur bestimmung eines polyvalenten antigens und reagenz hierfuer.
ATE365921T1 (de) Immunologische zusammensetzung zum nachweis von blasenkrebs und verfahren zu ihrer verwendung
ATE210294T1 (de) Immunoassay vorrichtung und testverfahren zu seiner verwendung
ATE208040T1 (de) Immunoassay-reagenzien, testsätze und verfahren
DE69521145D1 (de) Verfahren zur kompetitiven bestimmung eines haptens
EP1016866A4 (en) COMPOUND 2-AMINO-3 [2- (a) -MANNOPYRANOSYL) INDOL-3-YL] PROPIONIQUE, METHOD FOR THE PRODUCTION AND METHODS FOR IN VIVO EXAMINATION WITH THE NEW COMPOUND
DE69922680D1 (de) Detektion und quantifikation von vancomycin in den biologischen flüssigkeiten
DE60143227D1 (de) Vorrichtung und verfahren zur bestimmung des eintretens und vorhandenseins septischer bedingungen
DE59913949D1 (de) Humane monoklonale antikörper gegen inselzellantigen ia-2
DE69518182D1 (de) Methode zur Bestimmung einer Substanz